[Rare pulmonary (alveolar) diseases--clinico-morphological and etiopathogenic aspects]

Vutreshni Bolesti
|March 3, 2001
PubMed

Insights

This review explores the rare pulmonary diseases pulmonal microlythiasis, proteinosis, and primary idiopathic amyloidosis. New findings on pulmonary surfactant offer insights into their causes and development.

Area of Science:

  • Pulmonology
  • Pathogenesis Research
  • Rare Lung Diseases

Context:

  • Focuses on three exceptionally rare pulmonary conditions: pulmonal microlythiasis, proteinosis, and primary idiopathic amyloidosis.
  • Highlights the limited existing literature and the need for increased understanding among specialists and general practitioners.
  • Emphasizes the diagnostic challenges posed by the rarity and insufficient investigation of these diseases.

Purpose:

  • To review the latest international scientific literature on the etiology and pathogenesis of these rare pulmonary diseases.
  • To outline recent data on the role of pulmonary surfactant in the pathogenesis of these conditions.
  • To consolidate and disseminate existing knowledge, aiding in the diagnosis and management of these uncommon diseases.

Summary:

  • Reviews the etiology and pathogenesis of pulmonal microlythiasis, proteinosis, and primary idiopathic amyloidosis.
  • Discusses the role of pulmonary surfactant, including its structure, production, and recycling, in the development of these diseases.
  • Integrates new research findings to clarify the previously unsettled etiology of these rare lung disorders.

Impact:

  • Enhances the knowledge base for pulmonologists and general practitioners regarding rare pulmonary diseases.
  • Provides a foundation for further research into the mechanisms underlying these conditions.
  • Aims to improve the recognition and clinical management of patients with pulmonal microlythiasis, proteinosis, and primary idiopathic amyloidosis.

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Atelectasis II: Pathophysiology01:10

Atelectasis II: Pathophysiology

Atelectasis develops when alveoli lose their air and collapse inward. Because lung tissue is naturally elastic, these air sacs shrink rather than remaining open. Collapsed alveoli are no longer ventilated, reducing their role in gas exchange. Blood flow may continue in these regions, creating a ventilation–perfusion mismatch. Clinical findings include decreased breath sounds, dullness to percussion, reduced chest expansion, and decreased tactile fremitus as sound transmission through collapsed...
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...